By comparison, much higher doses (3–10 μM) were required to kill parental leukemia cell lines harboring TP53 alterations, in line with the notion that TP53 inactivation render cells insensitive to MDM2 inhibition [22] (Figure 4). The gene discussed is TP53; the disease is leukemia.